Corporate Fact Sheet 2H-2023
OVERVIEW
- Developing novel uses and delivery forms of drugs for infectious diseases, rare disorders, mental health
- Advancing clinical development of Bucillamine for infectious diseases (COVID-19) and ischemia reperfusion
- Novel uses and delivery (Thin film, Patch) of Psilocybin
- Robust patent portfolio(15 patents and patent applications)
- Prioritize development efforts targeting FDA regulatory
incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)
PRODUCT PIPELINE
EXPECTED MILESTONES 2H-2023
Complete reformulation of Bucillamine IV for future studies in infectious diseases and ischemia-reperfusion
IND-enabling studies of Psilocybin Patch
Phase 1/2 study - Psilocybin in Methamphetamine Disorder at University of Wisconsin
Psilocybin oral thin film strip development
MDMA patch for research purposes
CONTACT INFOMATION
Revive Therapeutics Ltd.
82 Richmond Street East
Toronto, ON M5C 1P1
Tel: 1-888-901-0036
E-mail:info@revivethera.com
Website:revivethera.com
STRATEGIC PARTNERS
TEAM
Management
Michael Frank, Chairman & CEO
Carmelo Marrelli, CFO
Derrick Welch, COO, Psilocin Pharma
Scientific and Clinical
Dr. Kelly McKee, CSO Dr. Arshi Kizilbash, M.D.
Dr. Osnesmo Mpanju, Regulatory Affairs
Dr. John Fahy, MD, Clinical and Scientific Advisor
Directors
Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon
STOCK INFORMATION
Ticker: | CSE: RVV, OTCQB: RVVTF, |
FRANKFURT: 31R | |
Share Price: | $0.035 (July 20, 2023) |
52-week High / Low: | CAD $0.485 / $0.02 |
Shares Outstanding: | 356,237,674 |
Market Cap: | CAD ~ 12,500,000 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Revive Therapeutics Ltd. published this content on 26 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2023 11:41:40 UTC.